[BIIB] Biogen Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 287.53 Change: 4.46 (1.58%)
Ext. hours: 292.98 Change: 5.45 (1.9%)

chart BIIB

Refresh chart

Strongest Trends Summary For BIIB

BIIB is in the long-term up 498% in 21 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. It provides AVONEX to treat relapsing MS; TYSABRI to treat relapsing forms of MS and Crohn?s disease; RITUXAN for treating relapsed or refractory, follicular, CD20-positive, and B-cell Non-Hodgkin?s lymphoma (NHL); FUMADERM to treat severe plaque psoriasis in adult patients; FAMPYRA, an oral compound for the improvement of walking in adult patients with MS; TECFIDERA for the treatment of MS; and GAZYVA, an injection for intravenous infusion that treats an untreated chronic lymphocytic leukemia. The company?s products that completed Phase III clinical trials comprise ELOCTATE and ALPROLIX, an inherited disorder that inhibits blood coagulations; and Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a. Its products under Phase III clinical tri

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS17.73 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 3.19% Sales Growth - Q/Q1.44% P/E14.2
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA20.83% ROE27.76% ROI24.82%
Current Ratio2.2 Quick Ratio1.86 Long Term Debt/Equity0.19 Debt Ratio0.2
Gross Margin88.36% Operating Margin45.28% Net Profit Margin33.89% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities77.22 M Cash From Investing Activities-1.76 B Cash From Operating Activities1.78 B Gross Profit2.31 B
Net Profit927.28 M Operating Profit1.23 B Total Assets16.76 B Total Current Assets5.62 B
Total Current Liabilities2.56 B Total Debt579.47 M Total Liabilities4.19 B Total Revenue2.59 B
Technical Data
High 52 week383.83 Low 52 week219.29 Last close235.8 Last change-1.02%
RSI53.32 Average true range6.6 Beta1.03 Volume1.07 M
Simple moving average 20 days-0.53% Simple moving average 50 days0.76% Simple moving average 200 days-10.8%
Performance Data
Performance Week-2.67% Performance Month1.81% Performance Quart4.23% Performance Half-22.99%
Performance Year-27.62% Performance Year-to-date-30.73% Volatility daily1.64% Volatility weekly3.66%
Volatility monthly7.5% Volatility yearly25.97% Relative Volume178.46% Average Volume1.55 M
New High New Low

News

2019-12-09 11:10:57 | Investors Are Moving Back Into Resurgent Biotech ETFs

2019-12-09 09:42:02 | J&J Presents Data on CAR-T Therapy Drug and Imbruvica at ASH

2019-12-08 09:27:46 | Bulls And Bears Of The Week: Facebook, Intel, Netflix, Tesla And More

2019-12-06 16:31:52 | Biogen Edges Near Breakout — But Will Its Alzheimer's Drug Pass Muster?

2019-12-06 15:08:00 | Alzheimer’s expert says more clinical trials are needed for controversial Biogen drug

2019-12-06 11:52:06 | Biogen CEO on Controversial Alzheimer’s Drug: “There Is Hope”

2019-12-06 11:19:00 | Risks of Biogen Alzheimer’s Drug Are Clear, but Its Benefits Are Still Unproven, Says Raymond James

2019-12-06 10:58:00 | Cassava stock is up on Alzheimer's data

2019-12-06 10:22:00 | Money Is Moving Back Into Surging Biotech Funds

2019-12-06 09:55:31 | Biogen Analysts Divided Over Alzheimer's Drug Following CTAD Presentation

2019-12-06 09:30:02 | Biogen Up on New Data on Alzheimer's Candidate Aducanumab

2019-12-05 20:50:57 | After Biogen's big Alzheimer's drug data reveal, observers remain divided

2019-12-05 19:35:03 | Eisai, Partner Biogen Gain as Alzheimer’s Drug Studies Revived

2019-12-05 16:32:34 | Astellas-Audentes Deal Likely to Ignite More Acquisitions

2019-12-05 16:17:19 | 5 Top Stock Trades for Friday: RH, DG, KR, BIIB

2019-12-05 16:07:55 | Biogen Stock Pops: Here's What Happened In Its Alzheimer's Update

2019-12-05 16:06:00 | Biogen Stock Is Rising After a Presentation at an Alzheimer’s Conference

2019-12-05 14:50:56 | Wild Biotech Day Sparks $7.6 Billion Shuffle for Neurology Trio

2019-12-05 14:19:00 | Biogen stock climbs as investors shrug off analyst skepticism about Alzheimer’s drug

2019-12-05 14:01:07 | Biogen's CTAD Presentation On Aducanumab Elicits Mixed Response

2019-12-05 13:44:51 | Biogen Has More Hope Than Data for Alzheimer’s Drug

2019-12-05 12:56:00 | The Dow Goes Negative Despite a Glimmer of Hope on Trade

2019-12-05 12:22:00 | Biogen shares rise on Alzheimer's candidate data

2019-12-05 10:08:00 | Biotech Stocks Are Making Wild Moves Amid a Deluge of Trial Data

2019-12-05 09:51:20 | UPDATE 1-Novartis R&D boss says doesn't see big opportunity in oral SMA therapy

2019-12-05 08:51:01 | Aurinia's Lupus Candidate Succeeds in Pivotal Study, Stock Up

2019-12-05 08:15:00 | Biogen Shares Up After Alzheimer Drug Tests Show No New Concerns

2019-12-05 06:00:00 | Biogen to make case to skeptics for its controversial Alzheimer's drug

2019-12-05 02:14:46 | Biogen divulges more data on trials for Alzheimer’s drug

2019-12-05 02:00:00 | OPEC, Huawei, PG&E, Biogen, and a 2020 Recession? - 5 Things You Must Know

2019-12-04 10:25:03 | Biogen's Lupus Candidate Meets Endpoint in Phase II Study

2019-12-04 10:13:00 | Anavex shares rise in advance of Alzheimer's meeting

2019-12-04 10:02:03 | Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More

2019-12-03 11:22:46 | Cramer Weighs In On Biogen, Caterpillar And More

2019-12-03 09:29:02 | Biogen's Shares Down on Rating Downgrade by Baird Analyst

2019-12-03 09:26:27 | Where to Buy Booming Biotech ETFs

2019-12-03 07:30:10 | Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus CLE and Systemic Lupus Erythematosus SLE

2019-12-02 16:13:49 | Biogen Stock Is Facing A Crucial Test — Here's What You Need To Know

2019-12-02 13:56:00 | Biogen's shares drop on critical view of Alzheimer's data

2019-12-02 13:55:15 | Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade

2019-12-02 10:25:00 | Biogen’s Alzheimer’s Drug Won’t Get Approved, Analyst Says

2019-12-02 09:48:08 | Biogen Downgraded by Baird Analyst Over Move to Salvage Alzheimer’s Drug

2019-12-02 06:24:20 | Have Insiders Been Buying Biogen Inc. NASDAQ:BIIB Shares?

2019-12-01 09:30:15 | The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More

2019-11-28 22:24:52 | Hedge Funds Warming Up To Biogen Inc. BIIB Again

2019-11-27 10:09:03 | Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More

2019-11-27 08:52:01 | ChemoCentryx Up on Encouraging Rare Disease Candidate Data

2019-11-27 08:24:01 | The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion

2019-11-27 06:52:11 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2019-11-26 06:07:11 | 4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal